BRIVIACT
Brivaracetam is indicated for the treatment of partial-onset seizures. The medication is approved for use in a broad patient population, including adults and pediatric patients as young as one month of age. It serves as an anticonvulsant therapy for managing these specific types of seizure events.
How BRIVIACT Works
The precise mechanism by which brivaracetam exerts its anticonvulsant activity is not fully known. The drug displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain. This interaction with the SV2A protein is believed to contribute to the medication's therapeutic effect.
Details
- Status
- Prescription
- First Approved
- 2016-02-18
- Routes
- ORAL, INTRAVENOUS
- Dosage Forms
- TABLET, SOLUTION
BRIVIACT Approval History
What BRIVIACT Treats
1 indicationsBRIVIACT is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Partial-Onset Seizures
Drugs Similar to BRIVIACT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BRIVIACT FDA Label Details
ProIndications & Usage
FDA Label (PDF)Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.